Short answer
PALVELLA THERAPEUTICS, INC. (PVLA) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 contains only incorporation-by-reference and liability disclaimers.
PALVELLA THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 contains only incorporation-by-reference and liability disclaimers
- No operating results, financial figures, reporting period, or earnings release content provided
Item 7.01 · Regulation FD Disclosure
- Earnings call scheduled for August 4, 2026 with accompanying investor presentation
- Exhibit 99.2 contains presentation materials relevant to the company’s earnings update
- Reg FD filing makes the presentation publicly available to ensure equal investor access
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 results: $21.9M net loss, or $1.52 per share, versus $9.5M and $0.86 in Q2 2025
- Cash, equivalents and short-term investments of $250.6M support ongoing clinical development and planned commercialization activities
- Rolling NDA for QTORIN rapamycin in microcystic lymphatic malformations initiated, with completion targeted for second half 2026
- Planned standalone U.S. launch in first half 2027 remains contingent on FDA approval
- R&D spending rose to $12.5M from $5.1M, reflecting NDA preparation, manufacturing and expanded clinical programs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PALVELLA THERAPEUTICS, INC. 8-K filings
Get the next PVLA 8-K as it lands
Follow PVLA for push alerts, or ask the research agent what this filing means.